Evaluation of Th17-related cytokines and IFN<b>γ</b>production from blood mononuclear cells of moderate and severe asthmatic children reveals methylprednisolone does not decrease IL-22 levels

Sarinho, Emanuel Sávio Cavalcanti; Azoubel-Antunes, Adriana; Rêgo, Moacyr Jesus Barreto de Melo; Brayner-Cavalcanti, Mariana; Lins, Thiago Ubiratan Lins e; Pitta, Ivan da Rocha; Pitta, Maíra Galdino da Rocha

doi:10.3109/02770903.2014.959129

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The source of the glucocorticoid‐sensitive IL‐17A in those patients was not identified. Glucocorticoid inhibition of IL‐6 could underlie glucocorticoid inhibition of IL‐17A in some asthma patients as methylprednisolone downregulates IL‐6, IL‐17A, and IFN‐γ in stimulated PBMCs from asthmatic children . A recent trial using brodalumab (anti‐IL‐17RA) suggests possible benefits in a select group of patients with highly reversible asthma .…”

Section: Wide‐ranging Glucocorticoid Sensitivity Of Diseases and Th17mentioning

confidence: 99%

Immunopathology alters Th17 cell glucocorticoid sensitivity

Banuelos

Cao

Shin

et al. 2016

Allergy

View full text Add to dashboard Cite

Th17 cells contribute to several inflammatory conditions and increasing evidence supports that Th17 cells are glucocorticoid resistant. However, Th17 cells in psoriasis and related diseases are glucocorticoid sensitive. We compare glucocorticoid sensitive and resistant immunological diseases and suggest that several aspects in Th-17 related diseases alter glucocorticoid sensitivity of Th17 cells. We identify molecular pathways that are implicated in glucocorticoid sensitivity of Th17 cells in the literature, as this information is useful for developing approaches to overcome glucocorticoid-resistant immunopathology.

show abstract

Section: Wide‐ranging Glucocorticoid Sensitivity Of Diseases and Th17mentioning

confidence: 99%

Immunopathology alters Th17 cell glucocorticoid sensitivity

Banuelos

Cao

Shin

et al. 2016

Allergy

View full text Add to dashboard Cite

show abstract

“…A previous study had found that oral GCs could decrease airway IL-17 in moderate-to-severe asthmatics (17). In vitro research showed that methylprednisolone could downregulate IL-17A levels in the supernatants of PBMCs from children with moderate and severe asthma (18). Fatemeh F et al found that ICS treatment could decrease the number of IL-17 + cells in bronchial submucosa from both atopic and nonatopic asthmatic patients (19).…”

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

ICS/LABA Combined With Subcutaneous Immunotherapy Modulates the Th17/Treg Imbalance in Asthmatic Children

et al. 2022

View full text Add to dashboard Cite

RationaleThe imbalance of T helper (Th17) cell and regulatory T (Treg) cell are involved in allergic asthma pathogenesis. We hypothesized that ICS/LABA could modulate the Th17/Treg imbalance and that subcutaneous immunotherapy (SCIT) could coordinate with ICS/LABA to rebalance the dysfunction of Th17/Treg.MethodsThirty house dust mites (HDM) allergic asthmatic children and fifteen healthy control subjects were enrolled in this study. Fifteen asthmatic children were treated by ICS/LABA powder inhalation, while the other fifteen asthmatic children were treated by ICS/LABA powder inhalation combined with HDM-SCIT. Asthmatic subjects were followed up for 6 months, but 2 asthmatics treated with ICS/LABA were lost to follow-up. Flow cytometry was used to determine the proportions of Th17 and Treg in CD4+ T cells from peripheral blood mononuclear cells (PBMCs). Serum levels of IL-17A and IL-10 were assessed by ELISA.ResultICS/LABA treatment significantly reduced the percentage of Th17 cells (1.252 ± 0.134% vs. 2.567 ± 0.386%), serum IL-17A (49.42 ± 2.643 pg/ml vs. 66.75 ± 3.442 pg/ml) and Th17/Treg ratio (0.194 ± 0.025 vs. 0.439 ± 0.072) compared to baseline (P<0.01). The ICS/LABA+HDM-SCIT treatment group showed similar reduction in the percentage of Th17 cells (1.11 ± 0.114% vs. 2.654 ± 0.276%), serum IL-17A (49.23 ± 2.131 pg/ml vs. 66.41 ± 2.616 pg/ml) and the Th17/Treg ratio (0.133 ± 0.015 vs. 0.4193 ± 0.050) (P<0.01). ICS/LABA+HDM-SCIT treatment group demonstrated elevated Treg percentages (8.483 ± 0.408% vs. 6.549 ± 0.299%) and serum IL-10 levels (127.4 ± 4.423 pg/ml vs. 93.15 ± 4.046 pg/ml), resulting in a lower Th17/Treg ratio than the ICS/LABA group.ConclusionICS/LABA treatment regulates Th17/Treg imbalance mainly by mitigating Th17-induced inflammation in asthma patients. The addition of SCIT further enhanced such effect by upregulating Treg cells.

show abstract

Berberine improves airway inflammation and inhibits NF-κB signaling pathway in an ovalbumin-induced rat model of asthma

Zheng

Zhang

et al. 2016

Journal of Asthma

View full text Add to dashboard Cite

show abstract

Evaluation of Th17-related cytokines and IFNγproduction from blood mononuclear cells of moderate and severe asthmatic children reveals methylprednisolone does not decrease IL-22 levels

Abstract: Methylprednisolone downregulated IL-6, IL17A, and IFNγ, but not IL-22, in stimulated PBMCs from asthmatic children indicating that methylprednisolone has no effect on IL-22 production by PBMCs.

Cited by 4 publications

References 20 publications

Immunopathology alters Th17 cell glucocorticoid sensitivity

Immunopathology alters Th17 cell glucocorticoid sensitivity

ICS/LABA Combined With Subcutaneous Immunotherapy Modulates the Th17/Treg Imbalance in Asthmatic Children

Berberine improves airway inflammation and inhibits NF-κB signaling pathway in an ovalbumin-induced rat model of asthma

Contact Info

Product

Resources

About